Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes,Alimentary Pharmacology & Therapeutics

当前位置： X-MOL 学术 › Aliment. Pharm. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Impacts of glucagon-like peptide-1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction-associated steatotic liver disease cirrhosis and type 2 diabetes
Alimentary Pharmacology & Therapeutics ( IF 7.6 ) Pub Date : 2024-03-27 , DOI: 10.1111/apt.17925
Mohamed I. Elsaid _{1,

2,

3} , Na Li ₄ , Stephen A. Firkins ₅ , Vinod K. Rustgi _{6,

7} , Electra D. Paskett _{8,

9} , Chathur Acharya ₄ , K. Rajender Reddy ₁₀ , Chien Wei Chiang ₁ , Khalid Mumtaz ₄

Affiliation

Department of Biomedical Informatics College of Medicine, The Ohio State University Columbus Ohio USA
Center for Biostatistics College of Medicine, The Ohio State University Columbus Ohio USA
Department of Internal Medicine, Division of Medical Oncology College of Medicine, The Ohio State University Columbus Ohio USA
Department of Internal Medicine, Division of Gastroenterology, Hepatology & Nutrition College of Medicine, The Ohio State University Columbus Ohio USA
Digestive Disease and Surgery Institute, Cleveland Clinic Cleveland Ohio USA
Division of Gastroenterology and Hepatology Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey USA
Center for Liver Diseases and Masses Rutgers Robert Wood Johnson Medical School New Brunswick New Jersey USA
Division of Population Sciences The Ohio State University Comprehensive Cancer Center Columbus Ohio USA
Department of Internal Medicine, Division of Cancer Prevention and Control College of Medicine, The Ohio State University Columbus Ohio USA
Department of Medicine University of Pennsylvania Perelman School of Medicine Philadelphia Pennsylvania USA

We examined the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) initiation on long-term Adverse Liver Outcomes (ALO) in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) cirrhosis and type 2 diabetes using real-world data from the MarketScan database.

中文翻译：

胰高血糖素样肽-1受体激动剂对代谢功能障碍相关脂肪肝病、肝硬化和2型糖尿病患者不良肝脏结局风险的影响

我们使用真实的数据检查了胰高血糖素样肽-1受体激动剂（GLP-1RA）起始治疗对代谢功能障碍相关脂肪性肝病（MASLD）肝硬化和2型糖尿病患者的长期不良肝脏结果（ALO）的影响。来自 MarketScan 数据库的世界数据。

更新日期：2024-03-27

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>